inclusion body myositis epidemiology forecast

Key Highlights

• In 2023, the diagnosed prevalence cases of Inclusion Body Myositis (IBM) was highest in the US among the 7MM, accounting for nearly 22.5 thousand cases which are further expected to increase by 2034.
• In the US, in 2023, ~15 thousand males and ~7.4 thousand females were affected with Inclusion Body Myositis (IBM).
• In 2023, Germany had the highest Inclusion Body Myositis (IBM)-diagnosed prevalence among EU4 and the UK, followed by France and  the UK. In contrast, Spain reported the lowest diagnosed prevalence of Inclusion Body Myositis (IBM) in the European region in the same year. As per DelveInsight’s analysis, diagnosed prevalence in EU4 and the UK is expected to increase at a significant CAGR by 2034.
• Epidemiological research on idiopathic inflammatory myopathies (IIM), particularly inclusion body myositis (IBM), is challenging due to its rare and heterogeneous nature, making it difficult to establish accurate prevalence rates. The lack of standardized diagnostic criteria, along with variations in clinical presentation and disease progression, further complicates efforts to understand its epidemiology on a global scale.

DelveInsight’s “Inclusion Body Myositis (IBM) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of Inclusion Body Myositis (IBM), historical and forecasted epidemiology of Inclusion Body Myositis (IBM) in the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The US
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2021-2034

Inclusion Body Myositis (IBM) Disease Understanding 

Inclusion Body Myositis (IBM) Overview

Inclusion body myositis (IBM) is an idiopathic inflammatory myopathy with characteristic muscle fiber degeneration and the presence of inclusions within muscle cells. It is classified under the broader category of idiopathic inflammatory myopathies, which also include polymyositis and dermatomyositis. IBM is a rare, progressive inflammatory muscle disorder characterized by muscle weakness and wasting. It primarily affects individuals over the age of 50 and is known for its slow onset and progressive nature. IBM is distinguished from other myopathies by specific pathological findings and its unique clinical presentation.

The symptoms of IBM are characterized by progressive muscle weakness, particularly affecting the proximal muscles, such as those in the hips and shoulders. Individuals with IBM may experience difficulty with activities that require fine motor skills, like typing or buttoning a shirt. Muscle wasting and atrophy are common, and patients may also struggle with dysphagia or difficulty swallowing, which can sometimes lead to respiratory issues. The weakness often starts symmetrically in the legs and arms, progressively impairing the ability to walk and climb stairs.

The exact cause of IBM remains unknown, but it is believed to involve an autoimmune mechanism where the body’s immune system attacks its muscle tissues. Genetic predisposition may also play a role, and there is some evidence suggesting environmental triggers could contribute. IBM is not typically associated with known infectious agents or other specific causes. IBM is characterized by the presence of intracellular inclusions, which are abnormal structures found within muscle fibers. These inclusions are thought to be a result of misfolded proteins and defective protein clearance mechanisms. Histological examination reveals rimmed vacuoles and the accumulation of abnormal proteins such as beta-amyloid and tau. The disease process involves both inflammatory and degenerative components, leading to progressive muscle fiber damage and weakness.

Inclusion Body Myositis (IBM) Diagnosis

Diagnosing IBM requires a comprehensive approach that includes clinical evaluation, laboratory tests, imaging studies, and muscle biopsy. The process begins with a clinical assessment to evaluate muscle strength and track the progression of symptoms. Blood tests are conducted to rule out other conditions and to identify any inflammatory markers. Electromyography (EMG) is performed to assess muscle electrical activity and confirm the presence of myopathic changes. A muscle biopsy is essential for identifying characteristic pathological findings, such as rimmed vacuoles and inclusions within muscle fibers, which are pivotal for a definitive diagnosis.

Further details related to diagnosis are provided in the report…

Inclusion Body Myositis (IBM) Epidemiology

For the purpose of designing the patient-based model for the Inclusion Body Myositis (IBM) epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by, Total Diagnosed Prevalent Cases of IBM, Age-specific Diagnosed Prevalent Cases of Inclusion Body Myositis (IBM), and Gender-specific Diagnosed Prevalent Cases of Inclusion Body Myositis (IBM) in the 7MM covering, the US, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2021 to 2034.

• According to DelveInsight Analyst, in the US, the highest number of age specific cases of IBM was observed in the 60─69 year age group (7,461 cases), followed by the 70─79 year age group (7,191 cases), 50─59 year age group (4,583 cases), with least cases occurring in those aged 80 years and above (3,307 cases).
• Japan had nearly 1,034 total diagnosed prevalent cases of Inclusion Body Myositis (IBM) in 2023, which are expected to increase at a CAGR of 0.4% by 2034.
• The DelveInsight analysis indicates that in Japan, males were more affected than females, with approximately 465 female cases and 569 male cases in 2023.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence. 

DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM Centers such as the Neuromuscular Medicine Division, Department of Neurology, Rochester, Minnesota, US; Department of Neurology, University of Kansas Medical Center, 66103, Kansas City, Kansas, US; Department of Neurology, Nagoya University Graduate School of Medicine, Japan; and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

• The report covers a segment of key events, an executive summary, descriptive overview of Inclusion Body Myositis (IBM), explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Inclusion Body Myositis (IBM) Report Insights

• Patient Population
• Country-wise Epidemiology Distribution
• Diagnosed Prevalent Cases of IBM
• Age-specific Diagnosed Prevalent Cases of IBM
• Gender-specific Diagnosed Prevalent Cases of IBM

Inclusion Body Myositis (IBM) Report Key Strengths

• 11 years Forecast
• The 7MM Coverage 
• Inclusion Body Myositis (IBM) Epidemiology Segmentation 
• Inclusion Body Myositis (IBM) Report Assessment
• Current Diagnostic Practices Patient Segmentation

Epidemiology Insights

• What are the disease risk, burdens, and unmet needs of Inclusion Body Myositis (IBM)? What will be the growth opportunities across the 7MM concerning the patient population of Inclusion Body Myositis (IBM)?
• What is the historical and forecasted Inclusion Body Myositis (IBM) patient pool in the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Why is the diagnosed prevalent cases of Inclusion Body Myositis (IBM) in Japan lower than the US?
• Which country has a high patient share for Inclusion Body Myositis (IBM)?

Reasons to Buy

• Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the Inclusion Body Myositis (IBM) prevalence cases in varying geographies over the coming years.
• A detailed overview of Gender and Age Grade-specific diagnosed prevalence of Inclusion Body Myositis (IBM), along with diagnosed prevalence of Inclusion Body Myositis (IBM) Based on severity of airflow limitation and diagnosed prevalence of Inclusion Body Myositis (IBM) based on symptoms and exacerbation history.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.